Across the pond...Nasdaq: KZIA, page-187

Well there you go....there will be some sort of data from PB.. Lets hope the Kazia drug gets a strong mention.​

From the big gapping this stock does....it is understandable, traders, investors look for dates of announcements​

USAAbstractOur understanding of how intracranial metastases genetically evolve from the primary tumors continues to be limited. In this presentation, I will present data from large-scale genomic efforts to characterize central nervous system metastases. We demonstrated that intracranial metastases have branched evolution, whereby the brain metastases and primary tumors shared a common ancestor yet both the primary tumor and brain metastasis continued to evolve independently. This implies that precision oncology approaches based on genetic characterization of primary tumors may be suboptimal for identification of therapeutic targets from which brain metastasis patients might benefit. We also show that comprehensive genomic characterization of brain metastases can lead to the discovery of putative metastatic drivers. Importantly, despite significant genetic divergence between the brain metastases and extracranial sites, there are common clinically actionable genetic alterations across brain metastases which have therapeutic potential. These data have now been translated to a NCI-sponsored cooperative group genomically-guided clinical trial (Alliance A071701)​